Better Buy: Moderna vs. Gilead Sciences

Keith Speights, The Motley Fool
·4 min read
Better Buy: Moderna vs. Gilead Sciences
Better Buy: Moderna vs. Gilead Sciences

Moderna (NASDAQ: MRNA) ranks as one of the leaders in the race to develop a coronavirus vaccine. Gilead Sciences (NASDAQ: GILD) developed remdesivir, which has quickly become a de facto standard of care in treating hospitalized patients with COVID-19. Moderna has trounced Gilead so far in 2020 in terms of stock performance, although Gilead's challenges have been unrelated to its coronavirus programs.